45. A filamentous bacteriophage particle according to claim 44 wherein said binding molecule is a scFv antibody molecule.

46. A filamentous bacteriophage particle according to claim 44 wherein said binding molecule is a Fab antibody molecule.

47. A filamentous bacteriophage particle according to claim 44 wherein said binding molecule is an antibody VH domain.

48. A filamentous bacteriophage particle according to any one of claims 44 to 47, which is in a population of filamentous bacteriophage particles displaying a population of said binding molecules having a range of binding specificities.

49. A method for producing a binding molecule specific for a particular target epitope or antigen, which method comprises the steps of:

producing a population of filamentous bacteriophage particles displaying at their surface a population of binding molecules having a range of binding specificities, wherein the binding molecules are selected from the group consisting of Fab antibody molecules, single-chain Fv antibody molecules and antibody VH domains and are able to bind target epitope or antigen, and wherein each filamentous bacteriophage particle contains a phagemid genome comprising nucleic acid with a nucleotide sequence encoding the binding molecule expressed from the nucleic acid and displayed by the particle at its surface;

selecting for a filamentous bacteriophage particle displaying a binding molecule with a desired specificity by contacting the population of filamentous bacteriophage particles with a target epitope or antigen so that individual binding molecules displayed on filamentous bacteriophage particles with the desired specificity bind to said target epitope or antigen.

50. A method according to claim 48 additionally comprising separating bound filamentous bacteriophage particles from the target epitope or antigen.

51. A method according to claim 49 additionally comprising recovering separated filamentous bacteriophage particles displaying a binding molecule with the desired specificity.

52. A method according to claim 50 additionally comprising producing in a recombinant system by expression from nucleic acid derived from said separated particles the binding molecule, or a fragment or derivative thereof with binding specificity for the target epitope or antigen, separate from filamentous bacteriophage particles.

53. A method according to claim 51 wherein said derivative comprises an Fc tail.

**REMARKS**

Enclosed with this page is a copy of the declaration filed in connection with U.S. patent application No. 07/971,857 from which the present application claims priority. More specifically, the present application is a continuation of U.S. patent application no. 08/484,893, which is a continuation of U.S. patent application no. 07/971,857 (now U.S. Patent No. 5,969,108).